Randomized Trials of Cancer Drugs Are For Yesterday
RCTs are expensive, slow and yield frustratingly limited information. (Nature Outlook)
Randomized Trials of Cancer Drugs Are For Yesterday Read More »
oncology
Actually, Many New Cancer Drugs May Be Helpful And Worth Trying
Perhaps the literature fails to capture the clinical value of oncology drugs. This could happen for several reasons.
Actually, Many New Cancer Drugs May Be Helpful And Worth Trying Read More »
Companion Diagnostics? For Cancer Care, We Need Better Ones
These biomarkers should link patients to optimal therapy (when such exists), and lead some to decline therapy that’s unlikely to
Companion Diagnostics? For Cancer Care, We Need Better Ones Read More »
Precision Medicine Will (Eventually) Lower Cancer Care Costs
Over time, the costs should drop, like for smartphone tech, what my Dad – a chemistry major and retired physician
Precision Medicine Will (Eventually) Lower Cancer Care Costs Read More »
Can Journalists Be Too Skeptical About Progress Against Cancer?
On Twitter this week, I happened upon a discussion having to do with the possibility of curing cancer.
Can Journalists Be Too Skeptical About Progress Against Cancer? Read More »
Lynparza, First In A New Class Of Cancer Drugs, Is Surprisingly Active In A Wide Range Of Tumors
So far, the studies demonstrate that Lynparza has activity in cancer patients with and without inherited BRCA mutations.